Abstracts Archive - Page 109 of 2425 - ACR Meeting Abstracts

Abstract Number: 1190 • ACR Convergence 2024
Cross-sectional Associations Among Sonographic and Radiographic Features and Symptoms Scores in a Population-Based Cohort
Katherine Yates¹, Carolina Alvarez², Sahar Sawani³, Liubov Arbeeva⁴, Todd Schwartz⁵, Serena Savage-Guin⁶, Jordan Renner⁷, Catherine Bakewell⁸, Minna Kohler⁹, Janice Lin¹⁰, Jonathan Samuels¹¹ and Amanda Nelson³, ¹University of North Carolina Medical Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴University of North Carolina, Chapel Hill, Carrboro, NC, ⁵University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁶Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill,, Chapel Hill, NC, ⁷Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Palo Alto, CA, ¹¹NYU Langone, Rye Brook, NY
Background/Purpose: Ultrasound (US) allows for visualization of features of knee osteoarthritis (KOA) including osteophytes, meniscal extrusion, synovitis, and cartilage damage. The current analysis aimed to…
Abstract Number: 1234 • ACR Convergence 2024
Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration
Nadine Henderson¹, Claud Theakston¹, Sulayman Chowhury¹, David Mott¹, Chris Skedgel¹, rita Freitas², Stefan Ivanicius³, Gudula Petersen³, Samantha Schofield³, Angie Botto-van Bemden⁴, Mickaël Hiligsmann⁵, Ricardo larrainzar⁶, Deborah Marshall⁷, Tommi Tervonen⁸ and David Walsh⁹, ¹Office of Health Economics, London, United Kingdom, ²Grünenthal GmbH, Aachen, Germany, ³Grunenthal GmbH, Aachen, Germany, ⁴Musculosketal Research International, Miami, FL, ⁵Maastricht University, Maastricht, Netherlands, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷University of Calgary, Calgary, AB, Canada, ⁸Kielo Research, Zug, Switzerland, ⁹University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Knee osteoarthritis (KOA) is a leading global cause of disability and chronic pain (Cross et al., 2014). It is well established that KOA affects…
Abstract Number: 1256 • ACR Convergence 2024
Higher Disease Activity in Pediatric Systemic Lupus Erythematosus Is Associated with a Greater Desire for Social Health Education: An Unmet Need in Pediatric Rheumatology
Kaitlin Kirkpatrick, Melodee Liegl, Ke Yan and Sara Sabbagh, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: There is limited evidence on the educational needs and preferences of caregivers and adolescents and young adults (AYA) with rheumatic disease (RD) regarding the…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 1242 • ACR Convergence 2024
Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms
Joseph F. Merola¹, Victoria Werth², Jiyoon C. Choi³, Brandon Becker³, Teresa Edwards⁴, Coburn Hobar⁵, Samantha Pomponi⁵ and Vibeke Strand⁶, ¹UT Southwestern Medical Center, Dallas, TX, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³Bristol Myers Squibb, Princeton, ⁴RTI International, Research Triangle Park, NC, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that disproportionately impacts women of childbearing age. Although the incidence varies widely based on ethnic…
Abstract Number: 1192 • ACR Convergence 2024
Relationship Between Measures of Fat Mass and Knee Osteoarthritis Incidence: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Douglas Kiel⁴, Michael Nevitt⁵, C.E. Lewis⁶, James Torner⁷ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Hebrew SeniorLife and Department of Medicine Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ⁵UCSF, Orinda, CA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Iowa, Iowa City
Background/Purpose: Obesity [defined by body mass index (BMI) ≥30 kg/m2] is an established risk factor for incident radiographic knee OA (ROA). However, the relative contributions…
Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Richard Warren¹, April W. Armstrong², Shinichi Imafuku³, Akimichi Morita⁴, Carle Paul⁵, Matthias Augustin⁶, Thierry Passeron⁷, Leon Kircik⁸, Eleni Vritzali⁸, Thomas Scharnitz⁹, Georgene Schroeder⁹, Subhashis Banerjee¹⁰ and Bruce Strober¹¹, ¹Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²University of California Los Angeles, Los Angeles, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁵Toulouse University and CHU, Toulouse, France, ⁶Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁷Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Bristol Myers Squibb, Princeton, ¹⁰Bristol Myers Squibb, Princeton, NJ, ¹¹Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 1138 • ACR Convergence 2024
Association Between Long-Term Exposure to Fine Particles and Its Components and the Onset of Systemic Autoimmune Rheumatic Diseases in Quebec
Mareva geslin¹, Julien Vachon², Naizhuo Zhao³, Elhadji Anassour Laouan Sidi², Sonia Jean⁴, audrey smargiassi² and Sasha Bernatsky⁵, ¹Universite de Montreal, Montreal, QC, Canada, ²Université de Montréal, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Institut national de santé publique du Québec, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Exposure to fine particles (PM2.5) has been associated with numerous health effects including with autoimmune rheumatic diseases (SARDs). While PM2.5 are composed of various…
Abstract Number: 1237 • ACR Convergence 2024
The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology
ADRIANA VANEGAS¹, Guillermo Quiceno², Luis Lira³, Gina Ochoa⁴, Álvaro Arbeláez-Cortés⁵, Mauricio Restrepo-Escobar⁶ and Virginia Pascual Ramos⁷, ¹HOSPITAL SAN VICENTE FUNDACION - UNIVERSIDAD DE ANTIOQUIA - Asociación Colombiana de Reumatología (ASOREUMA), MEDELLIN, Colombia, ²University of Tennessee Graduate School of Medicine, Dallas, TX, ³Sociedad Chilena de Reumatología, Santiago, Chile, ⁴Fundación LICAR, Barranquilla, Colombia, ⁵Clínica IMBANACO, Cali, Colombia, ⁶Universidad de Antioquia, Retiro, Colombia, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico
Background/Purpose: Scientific evidence supports that shared decision-making (SDM) can improve adherence to treatment, patient satisfaction, quality of life, clinical outcomes, and healthcare costs. However, challenges…
Abstract Number: 1042 • ACR Convergence 2024
Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
Racheal Githumbi¹, Steven Katz², Ania Kania-Richmond¹, Kim Giroux³, Yvonne Wallace³, Cheryl Barnabe¹, Glen Hazlewood¹, C. Allyson Jones², Amanda Steiman⁴, Anshula Ambasta¹, Diane Lacaille⁵, Elaine Yacyshyn², Jessica Widdifield⁶, Natasha Gakhal⁷, Tyler Williamson¹ and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Patient Partner, Calgary, AB, Canada, ⁴Sinai Health System, Toronto, ON, Canada, ⁵Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁶Sunnybrook Research Institute / ICES / UofT Institute of Health Policy, Management & Evaluation, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcome measures (PROMs) are essential tools for prioritizing patient-centric care and enhancing health system-performance measurement in rheumatology. Effective use of PROMs collected in…
Abstract Number: 1251 • ACR Convergence 2024
Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Xenofon Baraliakos¹, Victoria Navarro Compán², Elena Nikiphorou³, Thao Pham⁴, Francesco Ciccia⁵, Megan Hughes⁶, Bruno Kranz⁶, Anna Jus⁷, Chris Watson⁷, Jo Lowe⁸ and Sofia Ramiro⁹, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³King's College London, London, United Kingdom, ⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France, ⁵Università degli studi della Campania Luigi Vanvitelli, Naples, Italy, ⁶Adelphi Real World, Bollington, United Kingdom, ⁷Alfasigma S.p.A., Bologna, Italy, ⁸Axial Spondyloarthritis International Federation, London, United Kingdom, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: A survey was conducted to better understand the characteristics and management of axSpA and patient and physician perspectives on current treatment.Methods: In March 2024,…
Abstract Number: 1148 • ACR Convergence 2024
Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis
Nantakarn Pongtarakulpanit¹, Tanya Chandra¹, shiri keret², Eugenia Gkiaouraki³, Vladimir Liarski¹, Dana Ascherman³, Siamak Mogahadam¹, Chester Oddis¹ and Rohit Aggarwal⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a clinician-scored instrument that measures activity and damage in the skin of Dermatomyositis (DM)…
Abstract Number: 1243 • ACR Convergence 2024
A Patient-Focused Program for Using Steroids Wisely
John Stone¹, Michelle Petri², Jeffrey Gelfand³, Camille Kotton⁴, Jane McDowell⁵, George Papaliodis⁶, meredith Marinaro⁷, Matt Wilkinson⁸, Walter Lentfert⁹ and Martha Stone¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Harvard Medical School, Boston, MA, ⁵Queens University Belfast, Belfast, Ireland, ⁶Massachusetts General Hospital, Boston, MA, ⁷Novartis, Hartford, CT, ⁸UpThereEverywhere, London, United Kingdom, ⁹UpThereEverywhere, Wilmington, NC, ¹⁰Steritas, LLC, CONCORD, MA
Background/Purpose: Patients have no comprehensive, curated resource on steroid use to facilitate effective collaboration in their own care. Consequently, truly shared decision making around steroid…
Abstract Number: 1052 • ACR Convergence 2024
Challenges and Opportunities in Post-Pandemic Remote Therapeutic Monitoring for Musculoskeletal Disease
Angela Degrassi¹, Jeffrey Curtis², David Curtis¹, Kelly Gavigan¹, Laura Stradford³, Shelley Fritz⁴, Sandeep Sodhi⁵ and Shilpa Venkatachalam⁶, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of Alabama at Birmingham, Hoover, AL, ³Global Healthy Living Foundation, Nyack, NY, ⁴Global Healthy Living Foundation, Kalaheo, HI, ⁵Illumination Health, Hoover, AL, ⁶Global Healthy Living Foundation, New York, NY
Background/Purpose: Remote Therapeutic Monitoring (RTM) connects patients to their healthcare provider using a smartphone app with or without a physiologic biosensor device in an insurance-reimbursable…
Abstract Number: 1260 • ACR Convergence 2024
Toward a Treat-to-target Strategy in Juvenile Dermatomyositis: Seeking for Suitable Targets and Optimal Timing of Their Achievement
Silvia Rosina¹, Ana Isabel Rebollo-Giménez², Chiara Campone³, Valentina Natoli², Alessandro Consolaro², Francesca Bovis³ and Angelo Ravelli⁴, ¹IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, Genova, Italy, ³Università degli Studi di Genova, Genova, Italy, ⁴IRCCS Giannina Gaslini, Genoa, Italy
Background/Purpose: The management of juvenile dermatomyositis (JDM) is not standardized and no widely embraced therapeutic protocols are available. Furthermore, the optimal therapeutic targets as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].